secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2022-01-20T23:59:59+00:00
Accession:  0001171843-22-000369
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for Compass Therapeutics' CTX-009 Phase 2 study in biliary tract cancers
--------------------------------------------------------------------------------

- FDA cleared IND for CTX-009 bispecific antibody targeting DLL4 and VEGF-A.
- Enables global Phase 2 trial in advanced biliary tract cancers including cholangiocarcinoma.
- Will expand ongoing South Korean Phase 2; US clinical sites expected to open in Q2 2022.
- CEO Thomas Schuetz noted CTX-009 has potential as important new therapy for BTC patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184322000369/0001171843-22-000369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184322000369/f8k_012022.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-000369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer